Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

41.41USD
4:00pm EDT
Change (% chg)

$1.26 (+3.14%)
Prev Close
$40.15
Open
$39.80
Day's High
$41.43
Day's Low
$39.69
Volume
406,998
Avg. Vol
449,151
52-wk High
$67.10
52-wk Low
$30.10

Chart for

About

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and... (more)

Overall

Beta: 1.67
Market Cap(Mil.): $2,642.88
Shares Outstanding(Mil.): 65.83
Dividend: --
Yield (%): --

Financials

  PTLA.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -5.32 -- --
ROI: -90.28 -5.87 13.17
ROE: -139.93 -7.71 15.15

BRIEF-Portola Pharmaceuticals Receives $100 Mln Milestone Payment From Healthcare Royalty Partners For FDA Approval Of Andexxa

* PORTOLA PHARMACEUTICALS RECEIVES $100 MILLION MILESTONE PAYMENT FROM HEALTHCARE ROYALTY PARTNERS FOR FDA APPROVAL OF ANDEXXA® Source text for Eikon: Further company coverage:

May 24 2018

BRIEF-Portola Pharmaceuticals Q1 Loss Per Share $1.28

* PORTOLA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-U.S. FDA Approves Portola Pharmaceuticals’ Andexxa

* U.S. FDA APPROVES PORTOLA PHARMACEUTICALS’ ANDEXXA®, FIRST AND ONLY ANTIDOTE FOR THE REVERSAL OF FACTOR XA INHIBITORS

May 03 2018

BRIEF-Portola Pharmaceuticals Plans To Appeal Negative CHMP Opinion For Betrixaban In The European Union

* PORTOLA PHARMACEUTICALS RECEIVES AND PLANS TO APPEAL NEGATIVE CHMP OPINION REGARDING MARKETING AUTHORIZATION FOR BETRIXABAN IN THE EUROPEAN UNION

Mar 23 2018

EMA panel recommends against Portola's clot prevention drug

March 23 A panel of European Medicines Agency on Friday recommended against granting marketing approval to Portola Pharmaceuticals Inc's oral blood thinner, saying the benefits of the drug did not outweigh risks.

Mar 23 2018

BRIEF-EMA Panel Recommends Against Approval Of Portola Drug For Preventing Blood Clots Betrixiban

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL OF PORTOLA PHARMACEUTICALS' DRUG FOR PREVENTING BLOOD CLOTS BETRIXIBAN Source text (http://bit.ly/2pBz519) Further company coverage:

Mar 23 2018

BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study

* PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXA® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING

Mar 12 2018

BRIEF-Portola Pharmaceuticals Q4 Loss Per Share $1.41

* PORTOLA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 28 2018

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

Dec 22 2017

BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA® (BETRIXABAN)

Dec 19 2017

Competitors

Earnings vs. Estimates